文献速递消化、代谢与肾脏急症

阿替利珠单抗用于顺铂不耐受的局部晚期或转移性尿路上皮癌患者的一线治疗:一项单臂、多中心、2期试验

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
PubMed 文献 · Lancet · 2016-12-08
一句话结论在顺铂不耐受的局部晚期或转移性尿路上皮癌患者中,阿替利珠单抗一线治疗客观缓解率为23%,中位总生存期15.9个月。

这项单臂、多中心、2期研究在北美和欧洲7个国家的47个学术医学中心和社区肿瘤实践点招募了123例既往未治疗的顺铂不耐受的局部晚期或转移性尿路上皮癌患者,其中119例接受了至少一剂阿替利珠单抗1200 mg静脉注射、每21天一次直至进展。中位随访17.2个月时,独立中心评审的客观缓解率为23%(95% CI 16至31),完全缓解率为9%(n=11),27例缓解者中19例缓解持续中,中位缓解持续时间未达到。中位无进展生存期为2.7个月(2.1至4.2),中位总生存期为15.9个月(10.4至不可估计)。治疗相关不良事件发生率≥10%的为疲乏(36例,30%)、腹泻(14例,12%)和瘙痒(13例,11%),发生1例治疗相关死亡(脓毒症)。

要点

  • 顺铂不耐受的局部晚期或转移性尿路上皮癌患者一线接受阿替利珠单抗1200 mg静脉注射每21天一次,客观缓解率为23%(95% CI 16至31)。
  • 中位随访17.2个月时,完全缓解率为9%(n=11),27例缓解者中19例缓解持续中,中位缓解持续时间未达到。
  • 中位无进展生存期为2.7个月(95% CI 2.1至4.2),中位总生存期为15.9个月(95% CI 10.4至不可估计)。
  • 缓解在所有PD-L1表达亚组和不良预后因素亚组中均出现,肿瘤突变负荷与缓解相关。
  • 治疗相关不良事件≥10%为疲乏(36例,30%)、腹泻(14例,12%)、瘙痒(13例,11%),免疫介导事件14例(12%),1例治疗相关死亡(脓毒症),9例(8%)因不良事件停药。

适用人群与场景

  • 既往未治疗的局部晚期或转移性尿路上皮癌患者,且顺铂不耐受。
  • 研究在北美和欧洲7个国家的47个学术医学中心和社区肿瘤实践点进行。

处置流程与药物剂量

  • 阿替利珠单抗1200 mg静脉注射,每21天一次,直至疾病进展。

研究设计与关键结果

  • 研究类型:单臂、多中心、2期试验;样本量:入组123例,119例接受至少一剂阿替利珠单抗并纳入主要和安全性分析;人群:顺铂不耐受的既往未治疗局部晚期或转移性尿路上皮癌患者;干预:阿替利珠单抗1200 mg静脉注射每21天一次直至进展;主要终点:独立中心评审的客观缓解率(RECIST 1.1)。
  • 中位随访17.2个月时,客观缓解率为23%(95% CI 16至31),完全缓解率为9%(n=11),27例缓解者中19例缓解持续中,中位缓解持续时间未达到。
  • 中位无进展生存期为2.7个月(95% CI 2.1至4.2),中位总生存期为15.9个月(95% CI 10.4至不可估计)。
  • 缓解在所有PD-L1表达亚组和不良预后因素亚组中均出现;肿瘤突变负荷与缓解相关。
  • 治疗相关不良事件发生率≥10%:疲乏36例(30%)、腹泻14例(12%)、瘙痒13例(11%);1例治疗相关死亡(脓毒症);9例(8%)因不良事件导致停药;免疫介导事件14例(12%)。

证据类型、等级与局限

  • 证据类型:单臂、多中心、2期试验;未报告证据等级。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,阿替利珠单抗显示出令人鼓舞的持久缓解率、生存获益和耐受性,支持其用于未经治疗的转移性尿路上皮癌的治疗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: First-line chemotherapy for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma is associated with short response duration, poor survival, and high toxicity. This study assessed atezolizumab (anti-programmed death-ligand 1 [PD-L1]) as treatment for metastatic urothelial cancer in cisplatin-ineligible patients.

METHODS: For this single-arm, multicentre, phase 2 study, in 47 academic medical centres and community oncology practices in seven countries in North America and Europe, we recruited previously untreated patients with locally advanced or metastatic urothelial cancer who were cisplatin ineligible. Patients were given 1200 mg intravenous atezolizumab every 21 days until progression. The primary endpoint was independently confirmed objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1 (central review), assessed in prespecified subgroups based on PD-L1 expression and in all patients. All participants who received one or more doses of atezolizumab were included in the primary and safety analyses. This study was registered with ClinicalTrials.gov, number NCT02108652.

FINDINGS: Between June 9, 2014, and March 30, 2015, we enrolled 123 patients, of whom 119 received one or more doses of atezolizumab. At 17·2 months' median follow-up, the objective response rate was 23% (95% CI 16 to 31), the complete response rate was 9% (n=11), and 19 of 27 responses were ongoing. Median response duration was not reached. Responses occurred across all PD-L1 and poor prognostic factor subgroups. Median progression-free survival was 2·7 months (2·1 to 4·2). Median overall survival was 15·9 months (10·4 to not estimable). Tumour mutation load was associated with response. Treatment-related adverse events that occurred in 10% or more of patients were fatigue (36 [30%] patients), diarrhoea (14 [12%] patients), and pruritus (13 [11%] patients). One treatment-related death (sepsis) occurred. Nine (8%) patients had an adverse event leading to treatment discontinuation. Immune-mediated events occurred in 14 (12%) patients.

INTERPRETATION: Atezolizumab showed encouraging durable response rates, survival, and tolerability, supporting its therapeutic use in untreated metastatic urothelial cancer.

FUNDING: F Hoffmann-La Roche, Genentech.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2016. PMID: 27939400. doi:10.1016/S0140-6736(16)32455-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。